Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

Inclusion Criteria: * Male or female subjects aged 18 to 49 years, inclusive. * Individuals who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator. * The individual signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to regulatory requirements. * Individuals willing and able to comply with trial procedures and are available for the duration of follow-up. Exclusion Criteria: * Females who are pregnant or breastfeeding. * Gastroenteritis within 14 days before planned dosing (can warrant delay of trial vaccine administration). * Known hypersensitivity or allergy to any of the HIL-214 components (including excipients). * Known or suspected impairment/alteration of immune function, including history of any autoimmune disease or neuro-inflammatory disease. * Any serious chronic or progressive disease (including hepatitis B or C). * Previous exposure to an experimental norovirus vaccine. * Subject or subject's first-degree relatives are involved in the trial conduct.